FDA approval expands earlier use of Enhertu for metastatic breast cancer
The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...
clinicaladvisor.com3d
Brelovitug Granted Breakthrough Designation for Chronic Hepatitis Delta
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).
GlobalData on MSN12d
FDA breakthrough status for Bluejay’s CHD therapy brelovitug
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human ...
Yahoo Finance13d
Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Brelovitug (BJT-778) for the Treatment of Chronic Hepatitis Delta
"Breakthrough Therapy designation recognizes the potential of brelovitug to transform the lives of people living with CHD. We ...
Monthly Prescribing Reference13d
Brelovitug Granted Breakthrough Designation for Chronic Hepatitis Delta
Findings showed patients treated with brelovitug achieved 100% virologic response on all dosing arms. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Antara News12d
JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy ...
The Pharma Letter12d
BRIEF—Hopes of hepatitis D breakthrough with Bluejay’s brelovitug
Privately-held US biopharma Bluejay Therapeutics has announced that its lead product candidate brelovitug—also known as BJT-778—has received US Food and Drug Administration Breakthrough Therapy ...
Healio13d
Bluejay Therapeutics’ brelovitug secures FDA breakthrough status for chronic HDV
The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic hepatitis delta, for which no approved therapies currently exist in the U.S., the ...
Pharmabiz11d
US FDA grants breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for treatment of chronic hepatitis delta
US FDA grants breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for treatment of chronic hepatitis delta: Redwood City, California Thursday, January 23, 2025, ...
emjreviews.com13d
FDA fast-tracks brelovitug for treatment of chronic hepatitis D
The drug has been granted Breakthrough Therapy designation by the FDA for the treatment of chronic hepatitis delta (CHD).
The Bakersfield Californian13d
Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Brelovitug ...
Bluejay Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver diseases, today announced that ...